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Introduction
Previous studies suggest that HTLV-1 PVL remains con-
stant over time. We compare PVL, at baseline and fol-
low-up, in patients with rapidly progressive HAM/TSP
who received empirical treatment.
Methods
Rapidly progressive HAM/TSP was defined by patients’
incapacity to walk unaided within two years after symp-
toms’ onset. These cases are treated at our center with
prednisone in combination with Lamivudine and/or
Zidovudine at standard doses. PVL were performed by
duplicate in PBMC of blood samples drawn before
(baseline) and during treatment; values are reported in
copies /10
4 PBMC.
Results
We evaluated 11 patients (6 women); their median age
was 50 years-old, interquartile range [IQR] 20, with sig-
nificant differences between men and women (medians:
56 and 36, respectively, p=0.02). Median HAM/TSP
duration at diagnosis was 12 months (IQR 4). The med-
ian time (all in months) between the symptoms onset
and the beginning of therapy was 14 (IQR: 9); between
HAM/TSP onset and the baseline PVL, 14 (IQR: 13);
between PVL determinations, 7 (IQR: 7). Median PVL
values were 1183 (IQR: 1425) at baseline, and 1002 at
follow-up (IQR: 1425). In the group of 7/11 patients
where PVL decreased, differences between baseline and
follow-up determinations were significant (p=0.01), with
a median paired reduction of 362 (IQR: 1425). In the
four cases where PVL increased, differences were not
significant (p=0.06).
Conclusions
In most of the cases here reported, PVL decreased sig-
nificantly during empirical therapy. Clinical correlates
and long-term evaluation of these findings demand con-
trolled therapy trials.
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